GlaxoSmithKline and Stiefel to create new world-leading specialist dermatology business
Stiefel, the world's largest independent dermatology company, acquired by GSK in deal valued at up to $3.6 billion.
Read the full articleYou might also wanna read
GSK in talks to acquire Nuvalent for over $9 billion in largest deal in more than a decade
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to
cnbc.com·1mo ago
GSK in talks to buy cancer biotech Nuvalent for more than $9bn
Deal would rank as one of UK drugmaker’s biggest as biotech M&A activity accelerates this year
ft.trib.al·1mo ago
Pfizer-Mylan Merger: The Making of The Pharma Giant
Pfizer, Inc., is one of the world’s leading biopharmaceutical companies whose portfolio includes medicines, vaccines, and consumer healthcar
GSK acquires cancer drug developer Nuvalent in $10.6 billion deal
Biotech firm is developing small molecules for lung cancers
cen.acs.org·29d ago
Inside the BoF and Clinuvel Community Lunch Exploring the Future of Skin Health
Investors from Goldman Sachs, L Catterton and Bansk Beauty joined leaders from L’Oréal, Harrods, Space NK and Unilever at The Business of Be
businessoffashion.com·2d agoGermany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal
Merck KGaA's agreement to buy Bio-Techne for $11.3 billion strengthens its hold in life sciences, especially drug discovery and gene therapy
Comments
Sign in to join the conversation.
No comments yet. Be the first.